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Objective: To determine the factors associated with thyroid cancer, focusing on first-degree family history and 
ultrasonography (US) features, in euthyroid asymptomatic patients with thyroid nodules. 
Materials and Methods: This retrospective study included 1310 thyroid nodules of 1254 euthyroid asymptomatic patients 
who underwent US-guided fine-needle aspiration biopsy between November 2012 and August 2013. Nodule size and clinical 
risk factors–such as patient age, gender, first-degree family history of thyroid cancer, multiplicity on US and serum thyroid 
stimulating hormone (TSH) levels–were considered together with US features to compare benign and malignant nodules. 
Multiple logistic regression analysis was performed to assess the risk of thyroid malignancy according to clinical and US 
characteristics.
Results: Although all of the clinical factors and US findings were significantly different between patients with benign and 
malignant nodules, a solitary lesion on US (p = 0.041–0.043), US features and male gender (p < 0.001) were significant 
independent risk factors for thyroid malignancy in a multivariate analysis. Patient age, a first-degree family history of 
thyroid cancer and high normal serum TSH levels did not independently significantly increase the risk of thyroid cancer. 
However, multicollinearity existed between US assessment and patient age, first-degree family history of thyroid cancer and 
serum TSH values.
Conclusion: Ultrasonography findings should be the primary criterion used to decide the management of euthyroid 
asymptomatic patients with thyroid nodules. The concept of first-degree family history as a risk factor for thyroid malignancy 
should be further studied in asymptomatic patients.
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INTRODUCTION 
Some subtypes of thyroid cancer have several well-
known hereditary traits. The RET (tyrosine kinase receptor) 
proto-oncogene mutation, a proven genetic mechanism of 
medullary thyroid cancer, is found in both patients with 
multiple endocrine neoplasia type 2 and patients with 
sporadic cancers. Nonmedullary thyroid cancers (NMTCs) can 
also arise as thyroid involvement of genetic syndromes that 
result in multisystemic neoplasms. Causative mutations, 
such as inactivation of the adenomatous polyposis coli gene 
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in familial adenomatous polyposis or Gardener’s syndrome, 
the phosphate and tensin homolog gene mutation in 
Cowden’s syndrome, and the PRKAR1α mutation in Carney’s 
complex, have been reported (1). If a patient diagnosed as 
NMTC without the abovementioned genetic syndromes has 
two or more first-degree relatives with a history of thyroid 
cancer, he/she corresponds with the definition of familial 
nonmedullary thyroid cancer (FNMTC) (2), a condition 
suggested to be a subentity of NMTC that is inherited in an 
autosomal dominant pattern with incomplete penetrance 
(3).
Because the causative gene has not been identified, 
the only way to differentiate sporadic and familial cases 
is by the patients themselves reporting the number of 
affected first-degree relatives. However, as thyroid cancer 
has become one of the most common malignancies (4), 
a greater number of people will have a family history 
of thyroid cancer in the future. Today, ultrasonography 
(US) together with the serum hormone test for thyroid 
function is considered the gold standard modality for initial 
evaluation of thyroid nodules (5). Guidelines recommend 
the assessment of several clinical risk factors for thyroid 
malignancy, including family history, when planning the 
management of thyroid nodules (5, 6). However, the 
importance of known clinical risk factors reported before the 
era of widespread health checkups should be reconsidered. 
To our knowledge, there has been no study regarding family 
history as a risk factor for thyroid cancer in the euthyroid 
asymptomatic population that included US analysis as a 
confounding factor. Therefore, we investigated the factors 
associated with the presence of thyroid cancer, focusing 
on first-degree family history and US features, in euthyroid 
asymptomatic patients with thyroid nodules. 
 
MATERIALS AND METHODS
The Institutional Review Board of our institution approved 
this retrospective observational study and required neither 
patient approval nor informed consent for review of patient 
images and records. However, written informed consent was 
obtained from all patients prior to US-guided fine needle 
aspiration (US-FNA) as part of daily practice.
Patients
From November 2012 to August 2013, 2697 patients 
underwent US-FNA for initial evaluation of thyroid nodules 
at our institution. Among them, a total of 1310 nodules 
in 1254 patients were included if they satisfied the 
following criteria: 1) patients who had no recent history 
of medication for thyroid disease within 3 months; 2) 
patients in euthyroid status according to a reference serum 
thyroid stimulating hormone (TSH) level of 0.30–4.99 
μIU/mL, triiodothyronine (T3) 0.6–1.8 ng/mL, and free 
thyroxine (fT4) 0.70–1.48 ng/dL; 3) patients without 
any symptoms such as palpability, pain, or voice change; 
and 4) nodules with available standard references such 
as surgical pathology and Bethesda category II (benign) 
or VI (malignant) cytologic results, which are highly 
predictive of surgical pathology. Patients confirmed to have 
medullary or anaplastic thyroid cancer were excluded (Fig. 
1). Information on each patient’s family history of thyroid 
cancer was gathered from electronic medical records. To 
analyze the risk of malignancy, only family history among 
first-degree relatives–such as parents, siblings, sons, and 
daughters–regardless of histologic type was included (5). 
No patient had more than two direct family members with 
thyroid cancer. The mean age of the patients was 49.6 ± 
12.5 years (range, 17–87 years). The mean lesion size of 
the thyroid nodules was 13.3 ± 8.9 mm (range, 2–72 mm). 
Imaging Methods and Analysis
A 5–12 MHz linear probe (iU22, Philips Medical Systems) 
was used for US evaluation of all thyroid glands and cervical 
lymph nodes. Fourteen board-certified radiologists who 
were specialized in thyroid imaging with 1–18 years of 
experience performed the US examinations. US features used 
to describe the thyroid nodules were prospectively recorded, 
including internal component, level and homogeneity of 
echogenicity, margin, calcification, vascularity and shape 
at the time of US examination. US features considered 
suspicious for malignancy were: marked hypoechogenicity, 
microlobulated or irregular margin, microcalcifications, 
and taller than wider shape (7). If thyroid nodules showed 
one or more suspicious US features, they were regarded as 
suspicious malignant nodules. Nodules without any of the 
suspicious US features described above were classified as 
probably benign nodules. Nodule size was measured as the 
longest diameter. Multiplicity regardless of position in the 
ipsilateral or contralateral lobe of the thyroid gland was 
also recorded. Simple cysts or colloid cysts were excluded 
when evaluating multiplicity. 
US-Guided Fine-Needle Aspiration 
Ultrasonogaphy-FNAs were performed by the same 
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radiologists who performed the US examinations targeting 
either thyroid nodules with suspicious US features or 
the largest nodule with probably benign US features in 
cases in which no nodule showed suspicious US findings. 
Nodules smaller than 5 mm were not routinely aspirated, 
but biopsies were performed upon patient request. Each 
lesion was aspirated at least twice using a free-hand biopsy 
technique with a 23-gauge needle attached to a 20 mL 
disposable plastic syringe. The needles were disconnected 
from the syringes and the obtained materials were expelled 
onto glass slides, smeared, and fixed in 95% alcohol for 
Papanicolaou staining. One of seven cytopathologists 
interpreted the stained slides in the cytopathologists’ 
reading room with optional special staining if necessary. 
The Bethesda System for Reporting Thyroid Cytopathology 
was applied to the cytology reports of thyroid aspiration.
Statistical Analysis
We used cytopathological results as the “reference 
standard.” To evaluate the correlation between adolescence 
and old age with the risk of malignancy, we used the ages of 
20 and 60 years as cut-off values (8). We compared clinical 
characteristics including known risk factors associated with 
thyroid cancer and US assessment between benign and 
malignant nodules using the χ2 test for categorical variables 
and the independent t test for continuous variables. 
Multiple logistic regression analysis was performed to 
assess independent associations between thyroid cancer 
and all clinical factors with adjustment for the factors. 
Serum TSH levels were classified into three grades (low 
normal, mid-normal, and high normal) using cut-off values 
from a previous study (9). Odds ratios (ORs) with relative 
95% confidence intervals were also calculated. C-statistics 
were calculated to compare models with and without US 
characteristics and their subdivisions. The C-statistics of 
each model were compared using Delong’s method. The χ2 
test or independent two-sample t test was used to evaluate 
the multicollinearity of factors. Correlation between 
Fig. 1. Flow chart of case enrollment. FNA = fine-needle aspiration
2963 thyroid nodules in 2697 patients underwent FNA
1312 thyroid nodules in 1256 patients
1310 thyroid nodules in 1254 patients
2444 thyroid nodules in 2309 patients underwent the initial FNA
2393 thyroid nodules in 2261 patients
1615 thyroid nodules in 1536 patients
1810 thyroid nodules in 1712 patients with normal TFT
519 thyroid nodules in 490 patients with history of prior FNA on the same nodule
2 thyroid nodules in 2 patients with medullary or anaplastic thyroid cancer
51 thyroid nodules in 49 patients with recent medication history for thyroid disease within 3 months
583 thyroid nodules in 552 patients
1) 131 thyroid nodules in 122 patients with abnormal results in thyroid function test (TFT)
2) 452 thyroid nodules in 430 patients with no available TFT results
303 thyroid nodules in 293 patients without one of following standard references
1) Whose cytologic result was definite such as benign (category II) or malignant (category VI)
2) Whose surgical pathology was available
195 thyroid nodules in 190 patients with symptoms
1) 187 palpable lesions
2) 5 painful lesions
3) 3 with voice change
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presence of first-degree family history and malignancy risk 
in each final US assessment group was assessed by the χ2 
test or Fisher’s exact test. The Breslow-Day test was used to 
compare the homogeneity of the ORs between groups.
Analysis was performed using SAS (version 9.2, SAS 
Institute Inc., Cary, NC, USA). Statistical significance was 
assumed when the two-sided p value was less than 0.05. 
 
RESULTS 
Among the total 1310 nodules of the included 1254 
patients, 731 (55.8%) nodules were shown to be benign 
and the remaining 579 (44.2%) nodules malignant on 
cytopathology. There were 560 (42.7%) nodules that 
were pathologically confirmed postoperatively (Table 1). 
The mean age of patients with malignant nodules was 
significantly younger than that of patients with benign 
nodules (47.6 ± 12.8 years vs. 51.2 ± 12.0 years; p < 0.001). 
When the study population was classified according to 
age, patients between 20 and 60 years of age showed a 
higher rate of malignancy compared to other age groups 
(46.1% [485/1051] vs. 36.3% [94/259]; p = 0.004). The 
rate of malignancy was higher in male patients compared to 
female patients (50.5% [152/301] vs. 42.3% [427/1009]; 
Table 1. Pathology of 560 Nodules Confirmed Postoperatively
Benign (n = 32) Malignant (n = 528)
Adenomatous hyperplasia 24 Papillary carcinoma
Lymphocytic thyroiditis with adenomatous hyperplasia 4 Conventional 504
Lymphocytic thyroiditis 2 Follicular variant 17
Follicular adenoma 2 Diffuse sclerosiong variant 2
Warthin like type 2
Follicular carcinoma, minimally invasive 3
Table 2. Baseline Characteristics of 1310 Asymptomatic Thyroid Nodules
Benign Malignant P
No. of nodules 731 579
Mean age (years) 51.2 ± 12.0 47.6 ± 12.8 < 0.001
Age (years) 0.004
< 20 or > 60 165 (22.6%) 94 (16.2%)
20–60 566 (77.4%) 485 (83.8%)
Gender 0.014
Male 149 (20.4%) 152 (26.3%)
Female 582 (79.6%) 427 (73.7%)
1st degree family history 0.011
Yes 48 (6.6%) 63 (10.9%)
One 40 (5.5%) 57 (9.8%)
Two 8 (1.1%) 6 (1.0%)
No 683 (93.4%) 516 (89.1%)
Mean nodule size (mm) 16.0 ± 9.6 9.8 ± 6.4 < 0.001
Multiplicity 0.044
Solitary 222 (30.4%) 207 (35.8%)
Multiple 509 (69.6%) 372 (64.2%)
Serum TSH value
Mean TSH level (mIU/L) 1.6 ± 0.9 1.7 ± 0.9 0.075
TSH grade 0.024
0.3–1.39 381 (52.1%) 258 (44.6%)
1.4–2.49 242 (33.1%) 220 (38.0%)
2.5–4.99 108 (14.8%) 101 (17.4%)
US final assessment < 0.001
Probably benign 566 (77.4%) 49 (8.5%)
Suspicious malignant 165 (22.6%) 530 (91.5%)
1st degree = first-degree, TSH = thyroid stimulating hormone, US = ultrasonography
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p = 0.014). Patients with malignant nodules reported a 
family history of thyroid cancer more frequently than did 
patients with benign nodules (10.9% [63/578] vs. 6.6% 
[48/732]; p = 0.011). The mean size of the malignant 
nodules was 9.8 ± 6.4 mm, significantly smaller than the 
benign nodules (16.0 ± 9.6 mm; p < 0.001). Although a 
majority of malignant nodules were reported as one of 
synchronous multiple nodules (372/579, 64.2%), solitary 
nodules were significantly more malignant (48.3% [207/429] 
vs. 42.2% [372/881]; p = 0.044). The final US assessment 
was significantly associated with malignancy (p < 0.001). 
The mean serum TSH level was higher in malignant nodules 
than benign nodules, albeit not significantly so (1.7 ± 0.9 
years vs. 1.6 ± 0.9 years; p = 0.075). The proportion of each 
TSH grade differed slightly between benign and malignant 
nodules (p = 0.024) (Table 2).
Multivariate analysis of thyroid cancer according to 
clinical risk factors showed that patient age, male gender, 
presence of first-degree family history, and TSH grade 
increased the risk of malignancy (Table 3). However, 
on multivariate analysis including both clinical and US 
findings, only three factors–solitary lesion on US (p = 
0.041–0.043), US features, and male gender (p < 0.001)–
were independently associated with thyroid cancer. 
Table 3. Multivariable Analysis for ORs with 95% CIs of Thyroid Cancer According to Clinical Characteristics
Adjusted OR P Adjusted OR* P Adjusted OR† P
Age < 20 or > 60 0.694 (0.522, 0.923) 0.012 0.698 (0.524, 0.928) 0.013 0.695 (0.523, 0.924) 0.012
Male gender 1.394 (1.071, 1.814) 0.013 1.382 (1.062, 1.797) 0.016 1.365 (1.050, 1.774) 0.020
1st degree family history 1.618 (1.088, 2.405) 0.018 1.612 (1.084, 2.397) 0.018 1.655 (1.114, 2.458) 0.013
Solitary lesion on US 1.182 (0.933, 1.498) 0.167 1.180 (0.931, 1.495) 0.172 1.193 (0.942, 1.512) 0.143
Serum TSH level 1.171 (1.033, 1.327) 0.013
TSH grade 0.029
0.3–1.39 1
1.4–2.49 1.317 (1.031, 1.681) 0.027
2.5–4.99 1.415 (1.029, 1.947) 0.033
TSH grade
0.3–2.49 1
2.5–4.99 1.258 (0.931, 1.699) 0.135
C-statistics 0.591 (0.560, 0.622) 0.586 (0.555, 0.616) 0.580 (0.550, 0.610)
Numbers in parentheses are 95% CIs. *TSH levels were categorized into three groups: relatively low in normal range, mid-normal, 
relatively high in normal range, †TSH levels were categorized into two groups: low and mid normal, relatively high in normal range. 1st 
degree = first-degree, CIs = confidence intervals, OR = odds ratio, TSH = thyroid stimulating hormone, US = ultrasonography
Table 4. Multivariable Analysis for ORs with 95% CIs of Thyroid Cancer According to Clinical and US Characteristics
Adjusted OR P Adjusted OR* P Adjusted OR† P
Age < 20 or > 60 0.812 (0.550, 1.199) 0.295 0.810 (0.548, 1.196) 0.288 0.810 (0.548, 1.195) 0.288
Male gender 1.994 (1.360, 2.925) < 0.001 1.996 (1.362, 2.925) < 0.001 1.994 (1.361, 2.921) < 0.001
1st degree family history 1.278 (0.742, 2.203) 0.377 1.281 (0.743, 2.209) 0.373 1.283 (0.744, 2.211) 0.370
Solitary lesion on US 1.413 (1.014, 1.970) 0.041 1.409 (1.011, 1.965) 0.043 1.410 (1.012, 1.966) 0.043
Serum TSH level 1.046 (0.881, 1.242) 0.605
TSH grade 0.757
0.3–1.39 1
1.4–2.49 1.020 (0.729, 1.427) 0.907
2.5–4.99 1.176 (0.762, 1.816) 0.464
TSH grade
0.3–2.49 1
2.5–4.99 1.166 (0.776, 1.752) 0.461
US assessment 39.778 (27.953, 56.606) < 0.001 39.870 (28.003, 56.765) < 0.001 39.927 (28.065, 56.802) < 0.001
C-statistics 0.874 (0.855, 0.894) 0.874 (0.855, 0.894) 0.874 (0.855, 0.894)
Numbers in parentheses are 95% CIs. *TSH levels were categorized into three groups: relatively low in normal range, mid-normal, 
relatively high in normal range, †TSH levels were categorized into two groups: low and mid normal, relatively high in normal range. 1st 
degree = first-degree, CIs = confidence intervals, OR = odds ratio, TSH = thyroid stimulating hormone, US = ultrasonography
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Patient age, a family history of thyroid cancer, and high 
normal serum TSH levels or grades did not independently 
significantly increase the risk of malignancy (Table 4). 
C-statistics in models with US features were higher than 
in models without US features (0.874 vs. 0.580–0.591). 
C-statistics did not significantly differ according to how TSH 
levels were measured or categorized (p = 0.103 in the model 
including clinical characteristics only, p = 0.925 in the 
model including clinical characteristics and US assessment). 
However, there was multicollinearity between the final US 
assessment and other clinical risk factors, such as first-
degree family history, age, and serum TSH levels (Table 5).
There was no significant correlation between presence 
of first-degree family history and the risk of malignancy in 
each final US assessment group (p > 0.999 in the probably 
benign US group, p = 0.208 in the suspicious malignant US 
group), and the trends did not differ between groups (p = 
0.555).
DISCUSSION
Although all of the clinical factors were associated 
with thyroid cancer when analyzed individually, only two 
factors, solitary lesion on US and male gender, were found 
to increase the risk of malignancy, whereas a family history 
of thyroid cancer did not when US features were included 
in the analysis. As expected, US features surpassed clinical 
risk factors with high ORs, suggesting that asymptomatic 
thyroid nodules should be managed based primarily on US 
features. 
Increased risk of malignancy in a patient with familial 
history might be due to both a heredity effect and the 
sharing of a causative environment. Radiation (10), iodine 
deficiency (11), and some genetic syndromes (12) are widely 
accepted to be correlated with the risk of thyroid cancer, 
but their clinical implication in the general population has 
been limited.
To date, several genes or loci have been reported as 
possible candidates for the genetic background of NMTC, but 
the correlation between these mutations and thyroid cancer 
remains controversial (13). Overall, while a multi-genetic 
pathway has been hypothesized, it has not been verified. 
Therefore, the differentiation of FNMTC from sporadic cases 
simply follows the definition of FNMTC; the presence of two 
or more already diagnosed first-degree family members (2), 
theoretically based on calculations by Charkes (14) that 
demonstrated an ~99% chance of familial disease, with the 
probability decreasing by half when there were only two 
patients among first-degree relatives. The probability of 
thyroid cancer was reported to increase with an increasing 
number of affected first-degree family members (15). The 
familial tendency was most clearly demonstrated among 
sisters (16). Furthermore, other reports suggested the 
necessity of more aggressive evaluation and treatment 
including total thyroidectomy regardless of cancer size with 
routine central compartment neck dissection in familial 
cases due to the relatively high rate of multifocality/
lymph node metastasis (17, 18), relatively low reliability 
of FNA (19), and unfavorable clinical features and adverse 
outcomes of FNMTC (20-24).
However, as knowledge of thyroid cancer and financial 
support for health checkups have become available to 
the general population, a greater number of patients with 
indolent or early stage thyroid cancer are diagnosed by 
screening US. This trend will lead to an increase in the 
prevalence of patients with only a single family member 
with thyroid cancer history as well as FNMTC. Moreover, 
even patients who are regarded as sporadic cases at the 
time of this study might be revealed to be FNMTC when 
other family members with currently undetected cancers 
are diagnosed with thyroid cancer at a later date. Mazeh 
et al. (25) insisted that clinicians not overlook patients 
with a single family history, a possible subgroup of FNMTC, 
because these patients had a higher risk of malignancy 
compared to those without any family history. The next 
issue of interest is whether all patients with a family 
history of thyroid cancer should be regarded to be at risk 
of thyroid cancer. The problem is that the characteristics of 
the population diagnosed by screening US today might be 
different from that of the older generation of patients who 
were diagnosed at more advanced cancer stages based on 
Table 5. Association of Each Clinical Risk Factor with Final US 
Assessment
P
Age < 20 or > 60 0.007
Gender 0.723
1st degree family history 0.009
Solitary lesion on US 0.777
Serum TSH value
Mean TSH level (mIU/L) 0.001
TSH grade (3 categories) 0.001
TSH grade (2 categories) 0.168
P values from χ2-square test or independent two sample t test. TSH = 
thyroid stimulating hormone, US = ultrasonography
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the symptoms of thyroid cancer. Thus, we should question 
whether previous conclusions that regarded a first-degree 
family history of thyroid cancer as a risk factor for thyroid 
malignancy are valid in an era in which screening US has 
become commonplace.
In contrast to the inconclusive results regarding the 
clinical implications of family history as a risk and 
prognostic factor for thyroid cancer, the diagnostic value 
of US features is generally accepted. Many studies have 
shown that the malignancy rate of thyroid nodules is closely 
correlated with US findings (7, 26, 27). In our study, 
despite significant differences in the frequency of family 
history between patients with benign and malignant thyroid 
nodules, family history was not a significant risk factor 
for thyroid cancer in a multivariate analysis that included 
US features. However, there was a significant correlation 
between the final US assessment and other clinical risk 
factors, such as first-degree family history, age, and serum 
TSH levels (Table 5). Considering the multicollinearity of 
the factors and overwhelming significance of US features as 
a predictor of malignancy, we cannot disregard first-degree 
family history as a risk factor for thyroid cancer. However, 
we can deduce that additional consideration of the history 
of one or two first-degree family members with thyroid 
cancer may not be necessary for patient management after 
full evaluation of US features.
Although there are conflicting reports about gender as a 
risk factor for thyroid cancer (28, 29), current guidelines 
recommend that more attention be paid to male patients 
(6). Similar to other reports of a higher rate of malignancy 
in male patients with thyroid nodules (30-32), we found 
similar results in a multivariate analysis. Considering that 
male patients have worse prognosis of thyroid cancer than 
female patients (33, 34), a result confirmed in this study, 
meticulous US evaluation is needed so that such cases are 
not misdiagnosed.
It has been suggested that a solitary nodule is more 
likely to be malignant (30, 35-37), but other reports have 
suggested that the number of nodules is not correlated 
with malignancy (31, 38, 39). Some authors reported that 
the likelihood of malignancy per person was independent of 
multiplicity, but that the rate of malignancy had a negative 
correlation with the number of nodules in multinodular 
disease (40). The results of this study suggest that solitary 
nodules are at somewhat greater risk of malignancy than 
multiple nodules, but our results cannot support aggressive 
FNA in all solitary nodules due to the relatively low ORs.
There were several limitations to our study. First, some 
nodules were excluded due to a lack of determinative 
cytopathology. This resulted in the possibility of bias in 
patient selection. Second, we included nodules without 
follow-up cytology or surgical pathology and used the initial 
FNA results as a standard reference if the nodules were of a 
definitive category, such as benignity or malignancy. False-
negative or false-positive cytology might have influenced 
the results. Third, there might be bias derived from the 
small number of patients with a history of thyroid cancer 
among first-degree family members. Family history was 
rarely reported in our study population (8.5%, 111/1310), 
and FNMTC was found in only 0.9% of cases (12/1310), 
a percentage lower than previous reports. Fourth, we did 
not find a possible relationship between patients and 
relatives with thyroid cancer. A specific kinship, such 
as sisterhood, might have shown a different correlation 
with the rate of malignancy compared to other kinships, 
such as brotherhood or parenthood. Fifth, evaluation for 
adolescence as a risk factor was limited due to the small 
number of patients. Sixth, we did not include past patient 
history of thyroid disease or reproductive status as a factor 
in the analysis.
In conclusion, US findings should be the primary criterion 
used to decide the management of asymptomatic thyroid 
nodules. Clinical factors such as male gender or solitary 
nodule can be additionally considered. Further studies 
on whether first-degree family history is a risk factor for 
thyroid malignancy in the euthyroid asymptomatic group in 
the era of high-performance US should be performed.
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